May, 09 2019 12:06 JST

Source: Eisai

Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform

TOKYO, May, 09 2019 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.

In line with its medium-term business plan EWAY2025, Eisai is conducting research and development activities through various approaches at Eisai's global drug creation sites, in order to create next-generation drugs mainly in the "neurology" and "oncology" areas defined as Eisai's therapeutic areas of focus. Eisai is aiming to deliver novel benefits to patients and their families, by establishing the "Platform" via actively utilizing external big data and genomic data in addition to Eisai's own experience, know-how, and clinical data, as well as by building the "Ecosystem" via collaborating with partners such as other pharmaceutical companies, governments, medical organizations, care facilities, diagnostic developing companies, IT companies and insurance companies. As the first step, Eisai is proceeding with the efforts for the establishment of the dementia ecosystem.

In this investment business, Eisai invests approximately 3 billion yen per year for five years within the framework of 15 billion yen in total in venture businesses which can contribute to patient benefits that Eisai aims for by have synergy with Eisai's researches in the neurology and oncology areas, as well as having innovative digital technologies supporting the establishment of the ecosystem platform.

While Eisai begins this investment business in Tokyo to lead healthcare-related ecosystems in Japan, the company also plans to set up satellite offices in Cambridge, Massachusetts and San Francisco, California, two of the major clusters for digital health and biotech ventures in the United States, thus globally expanding investment areas.

Building on its long-cultivated capacity of global drug discovery and its network with local communities, Eisai is committed to utilizing this investment business to accelerate innovation in drug creation in agile cooperation with academia, drug discovery ventures, IT ventures, and strengthen the construction of the ecosystem platform as it seeks to further contribute to increasing the benefits provided to consumers, patients and their families in the world.

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.

Furthermore, we invest and participate in several partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting
May 29 2019 09:05 JST
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17 2019 15:34 JST
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16 2019 07:37 JST
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
May 10 2019 12:34 JST
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
May 10 2019 11:55 JST
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
May 09 2019 11:33 JST
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
May 08 2019 08:37 JST
Eisai Buys Out Purdue Rights to End Collaboration
May 01 2019 08:09 JST
Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting
April 24 2019 16:53 JST
Eisai Selected as Competitive ICT Strategy Company for 2019
April 24 2019 08:36 JST
More Press release >>

Latest Press Release

More Latest Release >>